Mankind Pharma Ltd (MANKIND) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003845, "name": "Mankind Pharma", "stock_name": "Mankind Pharma", "full_name": "Mankind Pharma Ltd", "name_url": "stocks-analysis/mankind-pharma", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "2,055.00", "chg": -27.55, "chgp": "-1.32%", "dir": -1, "prev_price": "2,082.55", "mcapval": "84,336.00 Cr", "mcap": "Large Cap", "scripcode": 543904, "symbol": "MANKIND", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE634S01028", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "3.62 lacs", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mankind-pharma-1003845-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Mankind Pharma Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/mankind-pharma-ltd-is-rated-sell-by-marketsmojo-3825750", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_mojoScore_3825750.png", "date": "2026-02-07 10:10:32", "description": "Mankind Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook." }, { "title": "Mankind Pharma Ltd Falls 3.08% Amid Volatile Week: 7 Key Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-ltd-falls-308-amid-volatile-week-7-key-market-signals-3825597", "imagepath": "", "date": "2026-02-07 10:04:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock hits 52-week low at Rs.2,053 amid downtrend</p>\n <p><strong>3 Feb:</strong> Intraday high of Rs.2,152.5 with 3.93% gain and sharp open interest surge</p>\n <p><strong>4 Feb:</strong> Intraday low at Rs.2,081 amid price pressure and elevated volatility</p>\n <p><strong>6 Feb:</strong> New 52-week low at Rs.2,029.35, closing the week lower</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,124.90</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Cl..." }, { "title": "Mankind Pharma Ltd Stock Falls to 52-Week Low of Rs.2029.35", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-ltd-stock-falls-to-52-week-low-of-rs202935-3824374", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_priceRelatedfactors_3824374.png", "date": "2026-02-06 11:26:11", "description": "Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2029.35 on 6 Feb 2026, marking a significant drop amid a three-day losing streak that has seen the stock fall by 4.87%. This decline comes despite the broader Sensex trading near its 52-week high, highlighting company-specific pressures within the Pharmaceuticals & Biotechnology sector." }, { "title": "Are Mankind Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-mankind-pharma-ltd-latest-results-good-or-bad-3821082", "imagepath": "", "date": "2026-02-04 19:24:22", "description": "Mankind Pharma Ltd's latest financial results for the quarter ending December 2025 reveal a complex picture of operational challenges despite some year-on-year growth metrics. The company reported net sales of ₹3,567.20 crores, reflecting an 11.52% increase compared to the same quarter last year. However, this figure also marks a sequential decline of 3.52% from the previous quarter, indicating a potential slowdown in revenue momentum.\n\nNet profit for the quarter stood at ₹408.75 crores, which is a 7.50% increase year-on-year, but it experienced a significant sequential drop of 20.09% from the prior quarter's profit of ₹511.51 crores. This decline in profitability is concerning, particularly as it coincides with a contraction in operating margins, which fell to 25.77% from 27.67% in the same period last year. The profit after tax (PAT) margin also decreased to 11.60%, down from 21.60% a year earlier, highli..." }, { "title": "Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-surge-amid-volatile-trading-3820823", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_oi_spurts_by_underlying_3820823.png", "date": "2026-02-04 15:00:32", "description": "Mankind Pharma Ltd (MANKIND) witnessed a significant 27.8% surge in open interest in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. This spike comes amid a volatile trading session where the stock underperformed its sector and approached its 52-week low, raising questions about directional bets and future price momentum." }, { "title": "Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-surge-amid-volatile-trading-3820771", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_oi_spurts_by_underlying_3820771.png", "date": "2026-02-04 14:00:25", "description": "Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This increase comes amid a backdrop of notable price volatility and underperformance relative to its sector peers, raising questions about potential directional bets and market sentiment towards the large-cap pharmaceutical stock." }, { "title": "Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-surge-amid-volatile-trading-3820720", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_oi_spurts_by_underlying_3820720.png", "date": "2026-02-04 13:00:24", "description": "Mankind Pharma Ltd (MANKIND) witnessed a significant surge in open interest (OI) in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. The stock, trading close to its 52-week low, experienced a 26.6% increase in OI alongside elevated volumes, reflecting a complex interplay of directional bets amid a volatile trading session." }, { "title": "Mankind Pharma Sees Sharp Open Interest Surge Amid Bearish Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-surge-amid-bearish-market-signals-3820654", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_oi_spurts_by_underlying_3820654.png", "date": "2026-02-04 12:00:29", "description": "Mankind Pharma Ltd has witnessed a significant 26.8% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock underperformed its sector and broader indices, trading near its 52-week low and reflecting bearish sentiment among traders." }, { "title": "Mankind Pharma Sees Sharp Open Interest Surge Amid Bearish Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-surge-amid-bearish-market-signals-3820587", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/MankindPharmaLt_oi_spurts_by_underlying_3820587.png", "date": "2026-02-04 11:00:22", "description": "Mankind Pharma Ltd has witnessed a significant 16.5% rise in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a notable price decline, with the stock closing near its 52-week low and underperforming its sector, raising questions about the underlying directional bets and market sentiment." } ], "total": 465, "sid": "1003845", "stock_news_url": "https://www.marketsmojo.com/news/mankind-pharma-1003845" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "04-Feb-2026", "details": "Please find attached intimation of participation in Investor Conference", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "04-Feb-2026", "details": "Please find attached intimation regarding newspaper advertisement - Unaudited Financial Results of the Company for Q3 FY26", "source": "BSE" }, { "caption": "Financial Result For The Quarter And Nine Months Ended December 31 2025", "datetime": "03-Feb-2026", "details": "Please find attached the Unaudited Financial Results for the quarter and nine months ended December 31 2025", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Mankind Pharma Ltd has declared <strong>100%</strong> dividend, ex-date: 08 Aug 25", "dt": "2025-08-08", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock hits 52-week low at Rs.2,053 amid downtrend

3 Feb: Intraday high of Rs.2,152.5 with 3.93% gain and sharp open interest surge

4 Feb: Intraday low at Rs.2,081 amid price pressure and elevated volatility

6 Feb: New 52-week low at Rs.2,029.35, closing the week lower

Week Open

Rs.2,124.90

Week Cl...

Read full news article

Mankind Pharma Ltd Stock Falls to 52-Week Low of Rs.2029.35

2026-02-06 11:26:11

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2029.35 on 6 Feb 2026, marking a significant drop amid a three-day losing streak that has seen the stock fall by 4.87%. This decline comes despite the broader Sensex trading near its 52-week high, highlighting company-specific pressures within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Mankind Pharma Ltd latest results good or bad?

2026-02-04 19:24:22

Mankind Pharma Ltd's latest financial results for the quarter ending December 2025 reveal a complex picture of operational challenges despite some year-on-year growth metrics. The company reported net sales of ₹3,567.20 crores, reflecting an 11.52% increase compared to the same quarter last year. However, this figure also marks a sequential decline of 3.52% from the previous quarter, indicating a potential slowdown in revenue momentum. Net profit for the quarter stood at ₹408.75 crores, which is a 7.50% increase year-on-year, but it experienced a significant sequential drop of 20.09% from the prior quarter's profit of ₹511.51 crores. This decline in profitability is concerning, particularly as it coincides with a contraction in operating margins, which fell to 25.77% from 27.67% in the same period last year. The profit after tax (PAT) margin also decreased to 11.60%, down from 21.60% a year earlier, highli...

Read full news article

Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading

2026-02-04 15:00:32

Mankind Pharma Ltd (MANKIND) witnessed a significant 27.8% surge in open interest in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. This spike comes amid a volatile trading session where the stock underperformed its sector and approached its 52-week low, raising questions about directional bets and future price momentum.

Read full news article

Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading

2026-02-04 14:00:25

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This increase comes amid a backdrop of notable price volatility and underperformance relative to its sector peers, raising questions about potential directional bets and market sentiment towards the large-cap pharmaceutical stock.

Read full news article

Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading

2026-02-04 13:00:24

Mankind Pharma Ltd (MANKIND) witnessed a significant surge in open interest (OI) in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. The stock, trading close to its 52-week low, experienced a 26.6% increase in OI alongside elevated volumes, reflecting a complex interplay of directional bets amid a volatile trading session.

Read full news article

Mankind Pharma Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-04 12:00:29

Mankind Pharma Ltd has witnessed a significant 26.8% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock underperformed its sector and broader indices, trading near its 52-week low and reflecting bearish sentiment among traders.

Read full news article

Mankind Pharma Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-04 11:00:22

Mankind Pharma Ltd has witnessed a significant 16.5% rise in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a notable price decline, with the stock closing near its 52-week low and underperforming its sector, raising questions about the underlying directional bets and market sentiment.

Read full news article